Company Details

A total of  9 international clinical research study on the treatment of asthma and COPD were successfully completed since 2009. We have three ongoing projects. Ongoing projects details are as follows:

1) The REACT Trial. Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 μg versus placebo. (Phase III study)

Study visits continue in accordance with the work plan. The estimated completion time of this project is in December 2013.

2) TONADO 1 Trial. Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) (Phase III study)

Study visits continue in accordance with the work plan. The estimated completion time of this project is in September 2013.

3) A randomized, placebo-controlled, dose-ranging, multicentre trial of QAW039 (1- 450 mg p.o.) to investigate the effect on FEV1 and ACQ in patients with moderate-to severe, persistent, allergic asthma, inadequately controlled with ICS therapy (Phase II study)

Study visits continue in accordance with the work plan. The estimated completion time of this project is in September 2013.

MESAM (Mersin Respiratory Research Center) is a company which located in the building of TECHNOPARK in the Mersin University Ciftlikkoy Campus, and was set up by a instructor of Mersin University Medical Faculty, Prof. Dr. Sibel Naycı, on 2009.

Until today, our company  have done R & D clinical trials in humans and presented scientific contributions by participating in the large number of international clinical research projects related to the development of new pharmaceutical products that can be used in the treatment of respiratory diseases, especially in asthma and chronic obstructive pulmonary disease (COPD).

MESAM has principle for participating in several international drug clinical research projects, which aimed at offering new products and innovative treatment alternatives in the respiratory health sector, as a center from the Turkey with links to major international research and development centers.

Accordance with this policy, MESAM  aims to provide a conribution from Turkey-Mersin to the licensing and supplying to the market of the innovative products, which have developed as a result of international research and development projects, in the world and also in Turkey

 

 

 

TEL: 0324 337 43 00 /1148

 

E-MAİL:3fxLKGvHNPRfRgVWkJrpVy1yLg==